Searchable abstracts of presentations at key conferences in endocrinology

ea0024p22 | (1) | BSPED2010

GHT does not improve QOL in all conditions

Eiser C , Wright N P , Butler G , Otero S C

Growth hormone treatment (GHT) is used to improve height, and potentially quality of life (QOL), in children with abnormal growth patterns. Previous QOL research suggests children with acquired growth hormone deficiency (AGHD) benefit more from GHT than those treated for other conditions.The aim was to determine child and parent reported QOL change over 1 year depending on GHT and diagnosis.One hundred and twenty-two children (mean...

ea0024p41 | (1) | BSPED2010

It’s not just Coeliac disease: gastroenterology referrals from a paediatric diabetes clinic

Lipscomb N C , Campbell E B , Imrie C

There is a well-recognised association between Coeliac disease and type 1 diabetes (T1DM). Four of our 68 patients have both conditions (5.9%). We present three other patients with T1DM and GI disease – two inflammatory bowel disease (IBD=2.9%) and one primary sclerosing cholangitis (PSC) and IBD (=1.5%).Case 1: Sixteen years old male, with T1DM from 13-year-old, developed diarrhoea and abdominal pain with no weight loss or blood pr. Investigation s...

ea0019oc13 | Neuroendocrine and Steroids | SFEBES2009

Inhibition of 11β-hydroxysteroid dehydrogenase type 1 promotes intra-retinal vascularisation in a murine model of ischaemic retinopathy

Dover A , Stitt A , McVicar C , Kitson C , Hadoke P , Walker B

Glucocorticoids possess potent angiostatic properties. 11β-Hydroxysteroid dehydrogenase type 1 (11βHSD1) amplifies local glucocorticoid action in a tissue-specific manner, and we have shown that inactivation of this enzyme enhances angiogenesis within sponges implanted subcutaneously, wounds and infarcted myocardium. 11βHSD1 is present within ocular tissues but its role in the pathogenesis of proliferative retinopathy is unknown. We hypothesised that inhibition ...

ea0019p8 | Bone | SFEBES2009

The potential inhibitory role of SOCS2 in chondrocyte GH/IGF-1 signalling during chronic inflammatory diseases

Pass C , MacRae V , Ahmed S , Farquharson C

The actions of SOCS2 on GH and IGF-1 signalling in growth plate chondrocytes have yet to be reported. During chronic paediatric inflammatory diseases retarded growth is seen in association with increased inflammatory cytokine levels, which is an effect that may involve SOCS2. The primary aim of this study was to investigate STAT signalling in chondrocytes in response to GH, IGF-1 and IL-1β. We also investigated the temporal expression of SOCS2 in response to GH and IGF-1 ...

ea0019p133 | Diabetes, Metabolism and Cardiovascular | SFEBES2009

Adrenal hypertrophy occurs in concert with insulin resistance following high fat feeding of two different strains of rat

McNeilly A , Williamson R , Balfour D , Sutherland C , Stewart C

The incidence of type 2 diabetes (T2DM) has doubled over the past decade. Obesity induced insulin resistance is associated with T2DM and the metabolic syndrome (including hypertension, and dyslipidemia). Diets high in saturated fat are largely to blame for the current obesity epidemic. High-fat feeding of animals increases circulating corticosterone levels, in addition to changes in glucose homeostasis. The relationship between insulin sensitivity and abnormal hypothalamic&#15...

ea0017oc15 | Diabetes 2 | BSPED2008

Extreme insulin resistance due to an insulin receptor mutation presenting as premature adrenarche evolving to polycystic ovarian syndrome in a non-obese girl

Wei C , Halsall DJ , O'Rahilly S , Semple R , Burren C

We report a non-obese 14-year old white female who initially presented to the paediatric endocrine service aged 7 years with adrenarche. She was born small for gestational age (2nd centile) but was otherwise developmentally normal with no significant past medical history. There was maternal history of polycystic ovarian syndrome (PCOS) but no family history of type 2 diabetes (T2DM). A GnRH test showed a pre-pubertal response and she was discharged after 1 year of follow-up wi...

ea0013p330 | Thyroid | SFEBES2007

Plasminogen activators in human thyroid follicular cells

Susarla Radhika , Watkinson John C , Eggo Margaret C

Human thyroid follicular cells in culture synthesise plasminogen activators, both urokinase (uPA) and tissue-type (tPA). The PAs secreted into the culture medium were active (2.5–50 U/ml) and able to mediate the conversion of plasminogen to plasmin. Secreted PA activity (PAA) was markedly increased by epidermal growth factor (EGF) and protein kinase C (PKC) activation with TPA. There was a corresponding increase in uPA and tPA mRNA levels and in uPA and tPA protein secret...

ea0012p33 | Cytokines, growth factors, growth and development | SFE2006

Effects of recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3) on human malignant pleural mesothelioma cell growth

Miraki-Moud F , Martinelli C , Camacho-Hübner C

Malignant pleural mesothelioma (MPM) is an asbestos-related tumour which is highly resistant to standard treatments, thus continuing to present a therapeutically challenge. Insulin-like growth factor system (IGFs), play an important role in the regulation of solid tumour cell growth. IGFBP-3, the most abundant circulating IGF binding protein, inhibits cell growth by both IGF-I dependent and independent pathways.The aim of our study was to evaluate the ef...

ea0012p73 | Neuroendocrinology and behaviour | SFE2006

Adrenomedullin in a rat model of multiple sclerosis

Barker S , Mongru R , Bolton C , Paul C

The vasoactive peptide adrenomedullin (ADM) has effects on several vascular beds including the cerebral circulation. The peptide has a positive impact on blood-brain-barrier (BBB) integrity, and transcription of ADM mRNA is enhanced by pro-inflammatory cytokines, IL-1 and TNF-alpha in neuronal cell types. The current study has investigated whether ADM may be a marker for disease progression, in vivo in experimental allergic encephalomyelitis (EAE), a model of the human disease...

ea0011p50 | Clinical case reports | ECE2006

Recurrent congenital neonatal hyperthyroidism in a mother with Graves’ disease (post radio-ablation) on thyroxine replacement

Kumar J , Rajendran P , Lapworth R , Buchanan C , Williams C

Thyroid dysfunction is not uncommon in pregnancy and is associated with various maternal, foetal and neonatal complications. We report the occurrence of neonatal hyperthyroidism in two successive pregnancies in a post radio-ablation mother with Graves’ disease who is on thyroxine replacement.Mother: A 30-year-old lady, treated for Graves’ thyrotoxicosis with radioiodine 10 years ago, was on thyroxine 100 mcg replacement for hypothyroidism. She ...